Survodutide Phase 3 Results and the Heart Trial Everyone Is Waiting For

The Quiet Contender Gets Loud

Most of the GLP-1 chatter this year has been about retatrutide, the triple agonist everyone wants. Meanwhile, a different drug has been stacking up Phase 3 data without the hype: survodutide, a once-weekly injectable from Boehringer Ingelheim that hits both the GLP-1 and glucagon receptors.

This weekend it gets a bigger spotlight. The American Heart Association Scientific Sessions run November 6 to 9 in Chicago, and the late-breaking program lists SYNCHRONIZE-CVOT, the survodutide cardiovascular outcomes trial, in a session on November 9. Results have not been presented as we write this, so this post is a preview. We will cover what is already confirmed, and what the heart trial can and cannot tell us.

What Survodutide Actually Is

Survodutide is an investigational dual agonist. The GLP-1 half works like the semaglutide lever: less appetite, slower stomach emptying, better blood sugar handling. The glucagon half is the twist. Glucagon signaling is thought to raise energy expenditure and push the liver to burn fat. That is the pitch, and the liver data below is why people take it seriously.

It is not approved anywhere. Boehringer and Zealand Pharma both describe it as an investigational agent that has not been approved for use. The FDA has granted it Fast Track (May 2021) and Breakthrough Therapy (September 2024) designations for adults with MASH and moderate or advanced fibrosis. Those are designations that speed development. They are not approvals.

Readout One: Obesity Without Diabetes (SYNCHRONIZE-1)

SYNCHRONIZE-1 was a 76-week, double-blind, placebo-controlled trial of 725 adults with obesity but no type 2 diabetes. People got survodutide 3.6 mg, 6.0 mg or placebo.

Using the efficacy estimand (which counts people who stuck with treatment), average weight loss was 15.3% on 3.6 mg and 16.6% on 6.0 mg, versus 3.2% on placebo. Using the treatment-regimen estimand (which counts everyone regardless of whether they stayed on drug), the numbers were 12.2% and 13.0% versus 5.4% on placebo.

That gap between estimands matters. The headline number is the best case for people who tolerated the drug. The conservative number is closer to what you would see in the real world. Both beat placebo comfortably, but a 13% figure and a 16.6% figure tell different stories, and honest coverage gives you both.

Readout Two: Obesity Plus Type 2 Diabetes (SYNCHRONIZE-2)

On October 1, 2026, results from SYNCHRONIZE-2 were presented at the European Association for the Study of Diabetes meeting in Milan and published in the New England Journal of Medicine. The trial enrolled 755 adults with obesity or overweight and type 2 diabetes, a group that usually loses less weight.

After 76 weeks, average weight loss was up to 13.1% on survodutide versus 3.1% on placebo (efficacy estimand). Up to 79.3% of people on the drug lost at least 5% of body weight, versus 32.7% on placebo. HbA1c fell by up to 1.21 percentage points from a baseline of 7.4%, compared with 0.03 on placebo. Waist circumference dropped by 11.1 cm versus 3.5 cm.

For context, a trial in people with diabetes landing at 13.1% is a solid result. It sits below the numbers we usually see in people without diabetes, which is the normal pattern for this drug class.

The Liver Angle Is the Real Story

Survodutide's differentiator is fatty liver disease. In SYNCHRONIZE-MASLD, a 48-week Phase 3 trial of 218 adults, up to 84.2% of people on the drug achieved at least a 30% relative reduction in liver fat, versus 24.3% on placebo. In an MRI substudy of SYNCHRONIZE-1, liver fat fell 63.1% on the 6.0 mg dose versus 24.5% on placebo.

An investigator quoted in coverage of the data argued the liver effects came earlier than weight loss alone would predict. That fits the glucagon mechanism, but a mechanism argument is not proof. The large Phase 3 MASH trials, LIVERAGE and LIVERAGE-Cirrhosis, are still running, and they are the ones that will show whether liver improvements turn into real clinical benefit.

A body composition substudy of 75 people also reported that no more than 10% of the lost tissue was muscle, with larger reductions in visceral and liver fat. Small substudy, so treat it as a promising signal and nothing more.

The Catch: Tolerability

This is not a free lunch. In SYNCHRONIZE-2, discontinuations due to gastrointestinal side effects were 18% on survodutide versus 1.2% on placebo. In SYNCHRONIZE-1 they were 17.8% (3.6 mg) and 20.2% (6.0 mg), versus 2.9% on placebo. Nausea, vomiting, diarrhea and constipation were more common, mostly during dose escalation.

Boehringer says the trial protocol allowed limited flexibility for managing side effects, and that current and upcoming studies use more individualized titration. That is a fair point, and a real open question. We will know more when those trials report. Until then, the honest read is that this drug has a meaningful GI dropout rate in its pivotal trials.

What the Heart Trial Is Testing

SYNCHRONIZE-CVOT is a Phase 3, randomized, double-blind, event-driven cardiovascular safety trial. Its primary endpoint is time to first occurrence of a 5-point major adverse cardiovascular event composite. Adults in the trial have a BMI of 27 or higher plus established cardiovascular or kidney disease, or multiple weight-related risk factors.

The key word is safety. This kind of trial asks whether the drug increases heart risk compared with placebo. A clean result would clear a hurdle for regulators. It would not by itself prove survodutide protects the heart, because a safety trial is designed to rule out harm.

One more caution on the data we already have: in SYNCHRONIZE-1, heart rate rose by about 3.2 to 3.5 beats per minute at week 76. Whether that matters over years is exactly the kind of thing an outcomes trial exists to check.

How It Stacks Up

We keep a few side-by-side pages if you want to dig in. See survodutide vs retatrutide, survodutide vs tirzepatide and survodutide vs semaglutide. The big caveat on any cross-trial comparison: different populations, different durations, different estimands. Do not line up headline percentages from separate trials and call a winner. Browse the full peptide database for more.

Our Take

Survodutide is a serious drug with real Phase 3 data, a differentiated liver story and a tolerability problem it still has to solve. The heart trial is the next gate. If the result is clean, expect the conversation to shift to filing timelines. If it is not, expect a lot of people to be surprised, because the cardiovascular effects of dual agonism were described by the trial investigators as unknown.

Whatever lands on Monday, read the actual paper or presentation, not the headline. And remember that regulators and pharma move slowly while the research community is already reading the data.

This article is educational content, not medical advice. Survodutide is an investigational drug and is not approved for use.

Sources

• AJMC: Dual agonist survodutide delivers up to 13.1% weight loss in T2D (Oct 1, 2026)
• Zealand Pharma company announcement No. 52/2026 (Oct 1, 2026)
• AJMC: Survodutide Phase 3 data signal metabolic gains beyond weight loss
• Radcliffe Cardiology: AHA Scientific Sessions 2026 late-breaking trials
• Pharmacy Times: AHA 2026 insights on survodutide